

Ref. No.: F.02(63)/RMSCL/ED (P) EMPANELMENT/DTL/NIB -10/2013/ 1170 dated 01.11.2013

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: rmsc@nic.in,
rmsc.drugprocurement@yahoo.in

**E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING
LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS
(Ending on 31.12.2015)**



!! सर्वे सन्तु निरामया:!!

LAST DATE OF SUBMISSION OF ONLINE BIDS: 10.12.2013 Upto 1:00 PM

Ministry of Health & Family Welfare
Government of Rajasthan
RMSCL
“Mukhyamantri Nishulak DavaYojana”
‘D’ Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: rmisc@nic.in

Ref. No.: F.02(63)/RMSCL/ED (P) EMPANELMENT/DTL/NIB -10/2013/ 1170 dated 01.11.2013

Notice Inviting E-Bids

E-bids are invited upto 1.00 PM of 10.12.2013 from approved Drugs Testing Laboratories situated in the state of Gujarat, Rajasthan, M.P., Haryana, Maharashtra, Himachal Pradesh and NCR of Delhi for analysis of Drugs. (Ending on 31.12.2015) Details may be seen in the Bidding Documents at our office or at the website of State Public procurement Portal <http://sppp.raj.nic.in>, www.dipronline.org, <http://eproc.rajasthan.gov.in> , www.rmisc.nic.in and may be downloaded from there.

Executive Director (Procurement)
RMSCL

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

RAJASTHAN

**E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING
LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS
(Ending on 31.12.2015)**

| | | |
|--|---|--|
| Bid Reference | : | F.02(63)/RMSCL/ED (P) EMPANELMENT/DTL/NIB -10/2013/ 1170 dated :01.11.2013 |
| Pre- bid conference | : | 14.11.2013 at 11.00 A.M. (RMSC meeting Hall) |
| Date and time for downloading bid document | : | 11.11.2013 from 6.00 PM |
| Last date and time for Downloading bid document | : | 09.12.2013 at 6.00 PM |
| Last date and time of submission of online bids | : | 10.12.2013 at 1.00 PM |
| Date and time of opening of Online technical bids | : | 10.12.2013 at 2.30 PM |
| Cost of the Bid Document | : | Rs. 2000/- |
| RISL Processing Fees | : | Rs. 1000/- |
| EMD | : | Rs. 20000/- |

**RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
RAJASTHAN**

**E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING
LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS
(Ending on 31.12.2015)**

“CONFIDENTIALITY IS THE ESSENCE OF THIS BID”

**1. LAST DATE FOR RECEIPT OF BIDS, BID FEES, EMD, RISL PROCESSING
FEES AND EMPANELMENT FEES**

- a) E-Bids [In Two Separate Bids (Technical Bid & Price Bid)] Will Be Received Till 1.00 PM on 10.12.2013 By The Rajasthan Medical Services Corporation Ltd, For The Empanelment Of Analytical Testing Laboratories For The Test And Analysis Of DRUGS (Ending on 31.12.2015)
- b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Earnest Money deposit.
- c) The e-Bids will be received on web-portal of e-procurement of GoR. Every Bidder will be required to pay the Bid form fee Rs. 2000.00 for downloaded from the website, EMD as applicable in Bid condition no. 6 and processing fee of Rs.1000.00 of R.I.S.L. through three separate prescribed challans (*format enclosed in Annexure- I*) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country upto 09-11.2013 or through D.D. / bankers cheque in favour of M.D. RMSCL (tender fees and EMD), MD, RISL (tender procession fees) physically in the office of RMSC by 1.00 PM on 10.11.2013. The bidders shall submit/upload scanned copy of all the challans in Technical Bid. Bids will be opened only after ensuring receipt of Bid fees along with processing fees and EMD. In the absence of Bid fees and processing fees and EMD the Bids will be rejected and will not be opened.

2 Eligibility Criteria for Empanelment :-

- (1) Drug Testing Laboratories should have valid Approval for carrying out test on drugs under the Drugs and Cosmetics Act, 1940 and Rules thereunder, with three years standing in the test & analysis and the lab shall be entitled for empanelment for the categories of items for which lab is having approval. Bid is invited from approved Drugs Testing Laboratories situated in the state of Gujarat, Rajasthan, M.P., Haryana, Maharashtra, Himachal Pradesh and NCR of Delhi.
- (2) The laboratory should be GLP compliant under the provisions of Drugs and Cosmetics Act, 1940 and Rules thereunder and should hold schedule L-1 certificate or should have NABL accreditation with proper scope of accreditation to undertake testing of drugs, surgical and sutures.
- (3) The laboratory should have an average annual turnover of not less than **Rs. 50 Lakhs towards drug, surgical and sutures testing services** for past preceding three years (2010-11, 2011-12, 2012-13).
- (4) The lab should have undertaken test and analysis of drugs and supplies of similar nature of at least three government institutions/corporation/reputed manufacturers of drug formulations.
- (5) The lab should not stand banned / debarred or blacklisted by any State or Central Government Organizations or its central procurement agencies on the due date of bid submission.
- (6) The laboratory and its responsible persons should not have been convicted under the provisions of applicable laws with regard to the activities and conduct of the laboratory.
- (7) The laboratory should have all necessary instruments/equipments/machines for testing of drugs with minimum three functional HPLC's.

3 TECHNICAL BID

The Bidder must furnish the following in technical bid.

- (a) Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be testing at **Annexure-VII**). **The bidder has to mentioned type of test for each item to be carried out by him, the filled up annexure VII to be submitted with**

technical bid.

- (b) The bidders shall submit/upload scanned copy of all the challans in Technical Bid deposited for Bid fees, RISL processing fee and Earnest Money, in case deposited in any branch of PNB throughout country. The required EMD / Tender fees/ RISL fee may be in form of physical D.D./ BC along with letter. D.D. / bankers cheque shall be in favour of M.D. RMSCL (tender fees and EMD), MD, RISL (tender procession fees).
- (c) Attested Photocopy of Analytical approval duly renewed up to date, issued by the State Licensing Authority.
- (d) Compliance of Schedule L-1 of Drugs & Cosmetics Rules, 1945 (GLP certificate)/Copy of NABL accreditation with scope for testing of drug formulations.
- (e) Documentary evidence of having analysed Drugs for the last three years with a statement in the proforma as given in **Annexure III**.
- (f) Attested copy of certificate of registration for service tax.
- (g) Non- Conviction Certificate by the State Licensing Authority/ competent authority .
- (h) *Annual turnover statement for 3 year i.e. 2010-11 , 2011-12 and 2012-13 certified by the practising Chartered Accountant.*
- (i) *Copies of the Balance Sheet and Profit and Loss Account for three years i.e. 2010-11 , 2011-12 and 2012-13 duly certified by the practicing Chartered Accountant.*
- (j) The following information in the form given in **Annexure IV (a) to IV(d)**.
 - a) The list of qualified personnel employed in the laboratory with proof of their qualifications and relevant approvals.
 - b) The list of sophisticated instruments available in the laboratory.
 - c) Micro Biological facilities available in the laboratory.
 - d) List of Reference Samples along with their date of procurement and quantities.
 - e) In the case of Non- Pharmacopoeial Products the Method of Analysis Should be appended to the Report, especially if the sample is declared

as “not of standard quality”.

k) A declaration in the proforma given in Annexure V duly signed and Notarized.

l) Details of Laboratory in Annexure – VI.

m) A copy of PAN issued by Income Tax Department.

n) **Documentary evidence for the constitution of the company / concern.**

4 PRICE BID :

The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). **BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only. The bidder should quote rate for the complete tests as applicable to the item. The rate for sterility test for sterile products should also be quoted separately at last entry of BOQ.**

5 OPENING OF TECHNICAL AND FINANCIAL EVALUATION

1. There after the Bidders found eligible as stated above on the basis of the examination on technical bid, the financial bid will be opened and after scrutiny thereof, including inspection of the laboratory, if required, the acceptable rates for analysis will be decided and communicated.

6 EARNEST MONEY DEPOSIT

The Earnest Money Deposit shall be Rs. 20,000/- The Earnest Money Deposit shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country up to 09.12.2013 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 1.00 PM on 10.12.2013 Earnest Money Deposit in any other form will not be accepted.

The Bids submitted without sufficient EMD will be summarily rejected. The EMD will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails

within specified time to sign the contract agreement or fails to furnish the security deposit.

7 GENERAL CONDITIONS

1. The details of the Drugs, to be analysed shall be given in **Annexure VII**.
2. The Bidder should quote the rates for complete analysis of each product and name of test to be performed, methodology to be used for each test should be mentioned in **Annexure-VII. However wherever rates for individual test are demanded, they should be furnished accordingly in BOQ. Wherever test are prescribed and their name and methodology for testing are not stated, such lab will not be considered responsive testing for such item.**
3. The rates quoted should be exclusive of taxes.
4. The rates quoted and accepted will be binding on the Bidder for the stipulated period and on no account any revision will be entertained till the completion of the BID period.
5. Analytical Laboratory, which also has its manufacturing activity, if empanelled by RMSC, then Samples of its own manufacturing unit shall not be sent to its empanelled laboratory for testing.
6. The laboratory will not be permitted to outsource any test from other laboratory.
7. RMSCL shall have the right to cause the laboratory to be inspected by the members of its technical committee before opening of price bid and subsequently as and when considered appropriate and based on the finding, the Bidder may be disqualified or de-empanelled, as the case may be.

8. ACCEPTANCE OF BID

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.
2. The Managing Director, Rajasthan Medical Services Corporation Limited reserves the right to accept or reject any BID for any one or more of the items Bided for, without assigning any reason.

9. AGREEMENT

1. The agreement with empanelled laboratories will remain valid up to 31.12.2015. This may be further extended for a further period of three months with mutual consent.
2. All Bidders who are empanelled will have to execute an agreement on a non-judicial stamp paper of value **Rs. 1000 /-** (Stamp duty to be paid by the Bidder), in favour of Managing Director, Rajasthan Medical Services Corporation Limited Jaipur within 15 days from the date of receipt of the intimation to them informing that their BIDs have been accepted. The form of agreement will be issued by RMSCL.
3. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.
4. All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

10. PERFORMANCE SECURITY

1. The successful Bidders shall be required to pay a security deposit of **Rs.50,000/-** *in the form of demand draft* at the time of execution of the agreement. **Performance security will be refunded three month after expiry of rate contract subject to successful completion of services.**

11. COMPLETE ANALYSIS & REPORTING CONDITIONS

1. (a) On empanelment and entrustment of the job, the Analytical Laboratory should furnish the test reports within:

I. 10 days from the receipt of the sample in case of Tablets, Capsules, Pessaries, Ointments, Powder and Liquid Oral Preparations (non – sterile products)

II. 21 days from the receipt of the sample in the case of I.V. Fluids and injectables and other items requiring test for sterility.

b) All the tests mentioned in IP/BP/USP/Drugs & Cosmetics Act. etc., (as the case

may be) should be carried out for each and every sample. The results obtained in the test should be mentioned in numerical value (wherever possible). However this condition will not apply when only specific testing is called for/desired on any particular sample.

- c) **“COMPLIES” or “PASSES” in the result column of the report is treated as incomplete report, if the result has some numerical value.**
 - d) **Every test report must have remarks either as “Standard Quality” or “Not of Standard Quality”. Any ambiguity/cutting in reports will not be accepted (clear mention of “standard quality or not of standard quality” should be stated in bold letters and crossing/cutting of one of these will not be accepted).**
 - e) Reports should be in A4 size (8.27” X 11.69”) paper of good quality.
 - f) Report should be issued on form 39 and should have S. no. , name of drug sample, code no., batch no., mfg. date, exp. date, description of tests, protocol of test specified & applied, findings & results obtained and should be signed by person-in-charge of testing. In case of Not of Standard Quality Reports the final results and reason for failure should be highlighted by pink / red highlighters.
 - g) Reports should be attached along with Spectra / Chromatography data sheets, if applicable and it will be considered incomplete if spectra or chromatograms are not attached.
- 2. All test reports of each batch of sample should be submitted to the RMSC in triplicate. In case of failure of a sample, the result should be communicated immediately to the Executive Director (Q.C.) through phone / E-mail and the report should be sent along with protocol.
 - 3. If in any circumstances (like break down of instrument, non-availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for a sample, the same should be reported within 24 hours of receipt of such a sample by phone or E-mail and the sample should be returned to the Executive Director (Quality Control), Rajasthan Medical Services Corporation Limited, Jaipur after taking necessary telephonic or mail consent. In case of

inability of laboratory to undertake the testing, a penalty of 25% of testing charges applicable for that product / products will be recovered.

4. If placebo or standard test procedure of any product is required the same should be demanded within 48 hours with return request. Period lapsed/taken in providing placebo or standard testing procedure will be condoned from prescribed time limit for that sample.
5. If any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the E.D. (Quality Control), Rajasthan Medical Services Corporation Limited Jaipur by Fax or E-mail.
6. The Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representative(s) has / have the right to inspect the laboratories of the Bidders who have submitted BIDs, before taking any decision regarding empanelment. Similarly, the Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representatives may also inspect any empanelled laboratory, at any point of time during the continuance of the BID and terminate / cancel its empanelment or any orders issued to the laboratory, not to entrust any further testing job to the laboratory based on facts brought out during such inspections.
7. **The successful lab shall have to make own arrangement for collection of sample, from RMSC Headquarters.**
8. **It will be sole discretion of RMSC to allot the samples to any empanelled lab in case when there are more than one lab approved for an item.**

12. PAYMENT PROVISIONS

1. No advance payment towards any analysis will be made to the empanelled Bidder.
2. No payment will be made for the incomplete analysis or incomplete report. Deliberate omission of any critical test will be viewed seriously and shall invite action against the laboratory as deemed fit by RMSCL.
3. Payments towards the analysis of Drugs will be made as per approved rate plus tax on it will be along with Tax at the prevailing rate as applicable at the time of payment.

13. PENALTIES

1. If the successful Bidder fails to execute the agreement and payment of security deposit within the time specified or withdraws the BID after intimation of the acceptance of the BID has been sent to or owing to any other reasons, he is unable to undertake the contract, the empanelment will be cancelled and the Earnest Money Deposit deposited by the Bidder shall stand forfeited in favour of the Rajasthan Medical Services Corporation Limited. Such Bidder(s) will also be liable for all damages sustained by the Rajasthan Medical Services Corporation Limited due to of breach of BID conditions. Such damages shall be assessed by the Managing Director, Rajasthan Medical Services Corporation Limited whose decision shall be final.
2. Non performance of any BID or empanelment conditions will disqualify a laboratory to participate in the BID for the period as decided by RMSCL.
3. If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Rajasthan Medical Services Corporation Limited, the Analytical Laboratory will be black listed for a period considered suitable. The Bidders shall also be liable for action under criminal law and the matter will be notified to the concerned Director of Drugs Control for suitable action against them under Drugs & Cosmetics Act & Rules.
4. The Managing Director, Rajasthan Medical Services Corporation Limited will be at liberty to terminate without assigning any reasons, the empanelment of any laboratory either wholly or in part at one month's notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
5. In all matters pertaining to the BID, the decision of the Managing Director, Rajasthan Medical Services Corporation Limited shall be final and binding.
6. (i) If the laboratory requires an extension in time for submission of test report, on account of occurrence of any hindrance he shall apply in writing for extension

on occurrence of hindrance but not after the stipulated date of *furnishing the test report*.

(ii) The Executive Director (QC)/ ADC (QC) may extend the testing period with or without liquidated damages in case they are satisfied that the delay in the submission of test reports is on account of any hindrances, he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of submission of report. Reasons shall be recorded.

(iii) **Extension in testing period:-** In case of extension in the testing period with liquidated damages the recovery shall be made on the basis of following percentages of *testing charges* which the Bidder has failed to submit:-

(a) Delay upto one fourth period of the prescribed testing period; 2.5%

(b) Delay exceeding one fourth but not exceeding half of the prescribed testing period; 5%

(c) Delay exceeding half but not exceeding three fourth of the prescribed testing period; 7.5%

(d) Delay exceeding three fourth of the prescribed testing period; 10%

Note: Fraction of a day in reckoning period of delay in *furnish the test report* shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

(iv) If, at any time during the continuance of this Agreement, the *laboratory* has, in the opinion of the Purchaser, delayed in submitting any test report, by the reasons of any riots, mutinies, wars, fire, storm, earthquakes, tempest or other exceptional cause, on a specific request made by the laboratory, the time for submitting test report may be extended by the *RMSCL* purely at his discretion for such period as may be considered reasonable. No further representation from the *laboratory* will be entertained on this account.

14. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit

price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;

- (ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.
- (iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

15. GRIEVANCE REDRESSAL DURING EMPANELMENT PROCESS:

The Designation and address of the First Appellate Authority is Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan.

The Designation and address of the Second Appellate Authority is Principal Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan and Chairman, RMSCL.

i. Filing an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

- ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.
- iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

- (a) Determination of need of empanelment;
- (b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;
- (d) Cancellation of a empanelment process;
- (e) Applicability of the provisions of confidentiality.

v. Form of Appeal

- (a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.
- (b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.
- (c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

(a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.

(b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.

(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

(i) Hear all the parties to appeal present before him; and

(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

16. COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:

Any person participating in a empanelment process shall-

a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;

b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;

- c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;
- d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;
- e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;
- f) Not obstruct any investigation or audit of a procurement process;
- g) Disclose conflict of interest, if any; and
- h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

17. Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

- a. Have controlling partners/shareholders in common; or
- b. Receive or have received any direct or indirect subsidy from any of them; or
- c. Have the same legal representative for purposes of the Bid; or
- d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or
- e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this

does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or

f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or

g. Bidder or any of its affiliates has been hired (or is proposed to be hired) by the Procuring Entity as engineer-in-charge/ consultant for the contract.

18. JURISDICTION

1. In the event of any legal dispute arising out of the BID such dispute would be subject to the jurisdiction of the Civil courts within the city of Jaipur only.

**Managing Director
Rajasthan Medical Services Corporation**

ANNEXURE- II
Ref. Clause No. 2 (3), 3(h)

ANNUAL TURN OVER STATEMENT

The Annual Turnover (*for drugs and medicines including Surgical and sutures testing services*) of M/s. _____ for the past three years are given below and certified that the statement is true and correct.

| S.No. | Years | Turnover in Lakhs (Rs) |
|-----------------------------|---------|------------------------|
| 1 | 2010-11 | |
| 2 | 2011-12 | |
| 3 | 2012-13 | |
| Total | | Rs. Lakhs |
| Average turnover per annual | | Rs. Lakhs |

Date:

Seal:

**Signature of Auditor/
Chartered Accountant
(Name in Capital)**

PROFORMA FOR PERFORMANCE STATEMENT
(for a period of last 3 years)

Name of the Laboratory : _____

Address: _____

| Types of Samples Analysed | No. of Samples Analysed during (2010-2011, 2011-12 & 2012-13) |
|---------------------------|--|
|---------------------------|--|

01. Tablets / Capsules / Pessaries/Dry Powders

02. Injectables

03. Liquid Preparations

04. Ointments / Creams / Gels

05. Others (Drugs)

06. Surgicals (Specify item names)

07. Sutures (Specify types)

08. Implants

09. Devices

Signature :

Date :

Name of the Lab :

Office Seal :

PERSONNEL IN QC DEPARTMENT

Name of the Technical Staff approved by State Licensing Authority along with his Designation, Highest Qualification, Experience (Experience relevant to analysis of drugs/surgical/sutures)

Signature :

Date :

Name of the Lab :

Office Seal :

LIST OF SOPHISTICATED EQUIPMENT/INSTRUMENT/APPARATUS
AVAILABLE IN THE LAB

| S.No. | Name of the Equipment Instruments / Apparatus | Make & Description | Date of Installation | Date of last Validation | Approved for testing of drugs from State licensing Authority since..... |
|-------|--|-----------------------|-------------------------|-------------------------------|---|
|-------|--|-----------------------|-------------------------|-------------------------------|---|

Signature :

Name of the Lab :

Date :

Official Seal:

FACILITIES IN THE MICROBIOLOGICAL SECTION

I. LIST OF STOCK CULTURES AVAILABLE

**II. LIST OF EQUIPMENT / APPARATUS AVAILABLE WITH DATE OF
INSTALLATION, make and approval from State Licensing Authority to permit
microbiological testing in the Lab.**

Signature :

Name of the Lab :

Date :

Official Seal:

**LIST OF REFERENCES SAMPLES ALONG WITH THEIR DATE OF
PROCUREMENT AND QUANTITIES**

Signature :

Name of the Lab :

Date :

Official Seal:

Affidavit
(on Non Judicial Stamp of Rs.100/-)

ANNEXURE – V
Ref. Clause No: 3(k)

DECLARATION FORM

1. I (Name of the Bidder) S/O_____, Age_____, resident of_____, am proprietor /Partner/Director having our office at_____ and the approved drug testing laboratory at_____ do hereby declare that I have carefully read all the conditions of BID of Rajasthan Medical Services Corporation Ltd., Jaipur, for the BIDs floated for empanelment of approved drugs testing laboratories for analysis of drugs. (ending on 31.12.2015) and shall abide by all the conditions set forth therein.
2. I further declare that I possess valid approval for testing of all the drugs/surgicals & sutures for which Price Bid have been submitted by me/us in Cover B and permission on Form 37 have been obtained for testing of these items from State Licensing Authority where ever applicable.
3. That the approval to test drugs/surgical & sutures have been obtained on Form 37 bearing No._____ which is valid/renewed up to_____.
4. That the Bidder firm is a proprietorship/Partnership/Pvt. Ltd./Ltd. firm and following are the other partners/directors:-

| S.No. | Name of Partner/Director | Age | Present & Permanent Address |
|-------|--------------------------|-----|-----------------------------|
|-------|--------------------------|-----|-----------------------------|

5. That our laboratory/Firm/Company does not stand blacklisted /debarred or banned on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission.
6. Our laboratory/Firm/Company also does not stand blacklisted, debarred or banned on the ground of wrong reporting of test results or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.

7. That i/we have carefully read all the conditions of bid in Ref. No.: F.02(63)/RMSCL/ED (P) EMPANELMENT/DTL/NIB -10/2013/ 1170 dated 01.11.2013 for the empanelment of analytical testing laboratories for the test and analysis of DRUGS (Ending on 31.12.2015) for Rajasthan medical services corporation and accept all conditions of bid, including amendments if any.
8. I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:
- a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
 - b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
 - c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
 - d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
 - e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition;
9. Our complete address for communication with phone no.:- -----

-----Pin code-----
10. E-mail address :- -----
11. Bank detail for e banking :-
Name of account holder
Full name of Bank with Branch

A/c no. with full digits.....

IFSC code

(Deponent)

Signature :

Date :

Name of the Lab :

Office Seal :

Verification

I.....S/o.....(Designation)..... Affirm
on oath that the contents/information from para 1 to 10 as mentioned above, are true &
correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if
any information furnished by me as above is found wrong, false, forged or fabricated; the
Corporation will be at liberty to cancel the Bid and forfeiting the earnest money deposit
and or performance security, for which I shall be solely responsible and the laboratory /
firm may be Debarred/Banned/ prosecuted for the same

(Name of Deponent & Signature)

ATTESTED BY NOTARY PUBLIC

DETAILS OF LABORATORY

1. Name of the Laboratory & Full Address :
Phone No (landline) :
Fax :
E-mail :
2. Other Branches & their Address (if any) :
3. Whether the firm has it own manufacturing unit? :
If yes give details of address, license number etc.
4. Date of Inception :
5. Approval No. & Date :
6. Issued by :
7. Valid up to :
8. Schedule L-1 certificate its no. and date of issue :
9. (i) NABL Accreditation no. & date
(ii) Scope of Accreditation
(iii) Its validity.
10. Name of the authorized signatory :
11. Specimen Signature of the authorized Signatory :
12. Names & Specimen Signatures of the Approved technical Staff who are authorized to sign the test reports :

ANNEXURE –VII
Ref: Clause no. 3 (a),7(1)

| S.N . | Code No. | Name of item with specification | Test proposed to be carried out | Remark |
|--------------|-----------------|--|--|---------------|
| 1. | 1 | Atropine Sulphate Injection IP 0.6 mg /ml (SC/IM/IV use) | | |
| 2. | 2 | Bupivacaine Hydrochloride in Dextrose Injection USP Each ml contains Bupivacaine Hydrochloride 5.0 mg. Dextrose 80.0 mg. | | |
| 3. | 4 | Bupivacaine Injection IP 0.5% | | |
| 4. | 5 | Drotaverine Hydrochloride Injection 40 mg/ 2 ml | | |
| 5. | 6 | Halothane BP | | |
| 6. | 7 | Isoflurane USP | | |
| 7. | 8 | Ketamine Injection IP 50 mg/ ml | | |
| 8. | 9 | Lignocaine Ointment 5% | | |
| 9. | 10 | Lignocaine and Adrenaline Inj. IP Each ml. Contains :- Lignocaine Hydrochloride IP 20 mg. Adrenaline IP 0.01 mg | | |
| 10. | 11 | Lignocaine and Dextrose Injection IP Each ml contains Lignocaine 50 mg and Dextrose (monohydrate) 75 mg | | |
| 11. | 12 | Lignocaine Gel IP 2% | | |
| 12. | 13 | Lignocaine injection IP 2% | | |
| 13. | 14 | Propofol Injection IP 10 mg/ ml | | |
| 14. | 15 | Thiopentone Injection IP 0.5 g | | |
| 15. | 16 | Aspirin Tablets IP 300mg | | |
| 16. | 19 | Diclofenac Sodium Injection IP 25 mg/ ml | | |
| 17. | 20 | Diclofenac Sodium Tablets IP 50 mg | | |
| 18. | 21 | Fentanyl Citrate Injection 50 mcg /ml | | |
| 19. | 22 | Ibuprofen and Paracetamol Tablets Ibuprofen 400 mg +Paracetamol 325mg | | |

| | | | | |
|-----|----|---|--|--|
| 20. | 23 | Ibuprofen Tablets IP 200 mg (Coated) | | |
| 21. | 24 | Ibuprofen Tablets IP 400 mg (Coated) | | |
| 22. | 25 | Morphine Sulphate Injection IP 10mg/ml | | |
| 23. | 26 | Paracetamol Drops (Each ml contains Paracetamol 150 mg) | | |
| 24. | 27 | Paracetamol Syrup IP 125mg/ 5 ml | | |
| 25. | 28 | Paracetamol Tablets IP 500 mg | | |
| 26. | 29 | Paracetamol Inj. 150mg/ml | | |
| 27. | 30 | Pentazocine Injection IP 30mg/ml (IM/IV Use) | | |
| 28. | 31 | Pethidine Hydrochloride Injection IP 50mg/ml (IM/IV use) | | |
| 29. | 32 | Tramadol Capsules IP 50 mg | | |
| 30. | 33 | Tramadol Injection 50 mg/ ml | | |
| 31. | 34 | Adrenaline Injection IP 1mg/ml (IM/IV use) | | |
| 32. | 35 | Betamethasone Tablets IP 0.5 mg | | |
| 33. | 36 | Cetirizine Tablets IP 10 mg | | |
| 34. | 37 | Chlorpheniramine Maleate Tablets IP 4 mg | | |
| 35. | 39 | Dexamethasone Injection IP 8 mg/2ml | | |
| 36. | 40 | Dexamethasone tablets IP 0.5mg | | |
| 37. | 42 | Hydrocortisone Sod. Succinate Injection IP 100 mg base / vial (IM/IV use) | | |
| 38. | 43 | Hydroxyzine Tablets 25 mg | | |
| 39. | 44 | Methyl Prednisolone Sodium Succinate for Injection USP 500 mg | | |
| 40. | 45 | Pheniramine Injection IP 22.75mg/ml | | |
| 41. | 46 | Hydrocortisone Sod. Succinate Injection IP (IM/IV use) | | |
| 42. | 47 | Prednisolone Tablets IP 5 mg | | |
| 43. | 48 | Promethazine Syrup IP 5 mg/ 5ml | | |
| 44. | 49 | Promethazine Injection IP 25mg/ ml | | |
| 45. | 50 | Promethazine Tablets IP 25 mg | | |
| 46. | 51 | Naloxone Injection IP 0.4mg/ ml | | |
| 47. | 52 | Pralidoxime Chloride Injection IP 25 mg/ml | | |
| 48. | 53 | Carbamazepine Tablets IP 200 mg (Film Coated) | | |

| | | | | |
|-----|----|--|--|--|
| 49. | 54 | Carbamazepine Tablets IP 100 mg (Film Coated) | | |
| 50. | 56 | Phenobarbitone Tablets IP 30 mg | | |
| 51. | 57 | Phenytoin Injection 50 mg/ml | | |
| 52. | 58 | Phenytoin Oral suspension IP 25mg/ml | | |
| 53. | 59 | Phenytoin Tablets IP 100 mg (Film Coated) | | |
| 54. | 60 | Sodium Valproate Injection 100 mg/ ml | | |
| 55. | 61 | Sodium Valproate Tablets IP 200 mg (Enteric Coated) | | |
| 56. | 62 | Acyclovir oral Suspension USP/BP 400mg/5ml | | |
| 57. | 63 | Acyclovir Tablets IP 200 mg | | |
| 58. | 64 | Acyclovir Tablets IP 800 mg | | |
| 59. | 65 | Albendazole Oral suspension 400 mg/10ml | | |
| 60. | 66 | Albendazole Tablets IP 400 mg | | |
| 61. | 67 | Amikacin Injection IP 100 mg | | |
| 62. | 68 | Amikacin Injection IP 500 mg | | |
| 63. | 69 | Amoxycillin and Cloxacillin Capsules 250mg + 250 mg | | |
| 64. | 70 | Amoxycillin and Potassium Clavulanate Tabs IP 500 mg + 125 mg | | |
| 65. | 71 | Amoxycillin Capsules IP 250mg | | |
| 66. | 72 | Amoxycillin Capsules IP 500mg | | |
| 67. | 73 | Amoxycillin Dispersible Tablets IP 125mg | | |
| 68. | 74 | Amphotericin B Injection IP 50 mg | | |
| 69. | 75 | Ampicillin Injection IP 500 mg | | |
| 70. | 78 | Azithromycin Tablets 100 mg Dispersible Tablets | | |
| 71. | 79 | Azithromycin Tablets IP 250 mg | | |
| 72. | 81 | Benzathine Benzylpenicillin Inj IP 12 lac units | | |
| 73. | 82 | Benzathine Benzylpenicillin Inj IP 6 lac units | | |
| 74. | 83 | Benzyl Penicillin Injection IP 600 mg Benzylpenicillin /Vial (10 Lac units) | | |
| 75. | 84 | Cefixime Tablets IP 100 mg | | |
| 76. | 85 | Cefixime Tablets IP 200 mg | | |
| 77. | 86 | Cefoperazone and Sulbactam for Injection Cefoperazone Sodium eq. to Cefoperazone 1 g and Sulbactam Sodium eq. to Sulbactam 0.5 g (IM/ IV use) | | |
| 78. | 87 | Cefotaxime Injection 1g | | |
| 79. | 88 | Cefotaxime Injection IP 250 mg | | |
| 80. | 89 | Ceftazidime Injection IP 1 g | | |

| | | | | |
|------|-----|---|--|--|
| 81. | 90 | Ceftazidime Injection IP 250 mg | | |
| 82. | 91 | Ceftazidime Injection IP 500 mg | | |
| 83. | 92 | Ceftriaxone Injection IP 125 mg | | |
| 84. | 93 | Ceftriaxone Injection IP 1g /vial | | |
| 85. | 94 | Ceftriaxone Injection IP 250 mg/ vial | | |
| 86. | 95 | Ceftriaxone Injection IP 500mg/vial | | |
| 87. | 96 | Cephalexin Capsules IP 250 mg | | |
| 88. | 97 | Cephalexin Capsules IP 500 mg | | |
| 89. | 98 | Chloroquine Phosphate Injection IP 40mg/ml | | |
| 90. | 99 | Chloroquine Phosphate Tab. IP 250mg (=155 mg of Chloroquine base) (Film Coated) | | |
| 91. | 101 | Ciprofloxacin Injection IP 200mg/100ml | | |
| 92. | 102 | Ciprofloxacin Tablets IP 250 mg Film Coated | | |
| 93. | 103 | Ciprofloxacin Tablets IP 500 mg film Coated | | |
| 94. | 104 | Clotrimazole Cream IP 2% w/w | | |
| 95. | 105 | Clotrimazole Vaginal Tablets IP 500 mg) | | |
| 96. | 106 | Compound Benzoic Acid Ointment IP Benzoic Acid 6%+ Salicylic Acid 3% | | |
| 97. | 107 | Co-trimoxazole Oral suspension IP Each 5 ml contains Trimethoprim 40 mg and Sulphamethoxazole 200 mg | | |
| 98. | 108 | Co-trimoxazole Tablets IP Trimethoprim 40 mg and Sulphamethoxazole 200 mg | | |
| 99. | 109 | Co-trimoxazole Tablets IP Trimethoprim 80 mg and Sulphamethoxazole 400 mg | | |
| 100. | 110 | Diethylcarbamazine Tablets IP 100 mg | | |
| 101. | 111 | Doxycycline Capsules IP 100 mg | | |
| 102. | 112 | Erythromycin Estolate Oral Suspension 125mg/5ml | | |
| 103. | 113 | Erythromycin Stearate Tablets 250mg | | |
| 104. | 114 | Fluconazole Tab. IP150mg. | | |
| 105. | 116 | Gentamycin Injection IP 80mg/2ml (IM/ IV use) | | |
| 106. | 117 | Griseofulvin Tablets IP 125 mg | | |
| 107. | 118 | Itraconazole Capsule 100 mg | | |

| | | | | |
|------|-----|---|--|--|
| 108. | 119 | Meropenem Injection IP 500 mg | | |
| 109. | 120 | Metronidazole Injection IP 500 mg/100ml | | |
| 110. | 121 | Metronidazole Benzoate Oral Suspension IP 100 mg of base/5ml | | |
| 111. | 122 | Metronidazole Tablets IP 200 mg (Film Coated) | | |
| 112. | 123 | Metronidazole Tablets IP 400 mg (Film Coated) | | |
| 113. | 124 | Norfloxacin Tablets IP 400 mg Film Coated | | |
| 114. | 125 | Ofloxacin Tablets IP 200 mg | | |
| 115. | 126 | Phenoxymethylpenicillin Potassium Tablets 125mg | | |
| 116. | 127 | Phenoxymethylpenicillin Potassium Tablets 250mg | | |
| 117. | 128 | Primaquine Tablets IP 2.5 mg | | |
| 118. | 129 | Primaquine Tablets IP 7.5 mg | | |
| 119. | 130 | Procaine Penicillin with Benzylpenicillin Injection IP 3+1 lac units | | |
| 120. | 131 | Quinine Dihydrochloride Injection 300 mg/ ml | | |
| 121. | 132 | Quinine sulphate Tablets IP 300mg (Film Coated) | | |
| 122. | 133 | Azathioprine Tablets IP 50 mg | | |
| 123. | 134 | Bleomycin Injection IP 15 units | | |
| 124. | 135 | Calcium Folate Tablets BP/Leucovorin Calcium Tablet USP Cal. Folate eq. to Folinic Acid /Leucovorin 15 mg | | |
| 125. | 136 | Chlorambucil Tablets IP 5 mg | | |
| 126. | 137 | Cisplatin Injection IP 50 mg/ 50 ml | | |
| 127. | 138 | Cyclophosphamide Injection IP 200 mg | | |
| 128. | 139 | Cyclophosphamide Injection IP 500 mg | | |
| 129. | 140 | Cyclosporin Capsules USP 25mg | | |
| 130. | 141 | Cytarabine Injection IP 100mg/ ml | | |
| 131. | 142 | Danazol Capsules IP 50 mg | | |
| 132. | 143 | Daunorubicin Injection IP 20 mg | | |
| 133. | 144 | Doxorubicin Injection IP 50 mg/ 25 ml | | |

| | | | | |
|------|-----|--|--|--|
| 134. | 146 | Etoposide Injection IP 100 mg/ 5 ml | | |
| 135. | 147 | Flunarizine Tablets 5 mg | | |
| 136. | 148 | Fluorouracil Injection IP 250 mg/ 5ml | | |
| 137. | 149 | L-Asparaginase Injection 10000 IU | | |
| 138. | 150 | Leucovorin Calcium Injection IP 10 mg /ml | | |
| 139. | 151 | Melphalan Tablets IP 5 mg | | |
| 140. | 152 | Mercaptopurine Tablets IP 50 mg | | |
| 141. | 153 | Methotrexate Injection IP 50 mg/ 2 ml | | |
| 142. | 154 | Methotrexate Tablets IP 2.5 mg | | |
| 143. | 155 | Paclitaxel Injection IP 260 mg | | |
| 144. | 156 | Paclitaxel Injection IP 100 mg | | |
| 145. | 157 | Tamoxifen Tablets IP 10 mg | | |
| 146. | 158 | Vinblastine Injection IP 10mg/ 10ml | | |
| 147. | 159 | Vincristine Injection IP 1mg/ ml | | |
| 148. | 160 | Levodopa and Carbidopa Tablets IP Levodopa 100 mg + Carbidopa 10 mg | | |
| 149. | 161 | Levodopa and Carbidopa Tabs IP 250 mg + 25 mg | | |
| 150. | 162 | Trihexyphenidyl Hydrochloride Tablets IP 2 mg | | |
| 151. | 163 | Acenocoumarol Tablets IP 2 mg | | |
| 152. | 165 | Deferasirox Tablets 100 mg | | |
| 153. | 166 | Deferasirox Tablets 500 mg | | |
| 154. | 167 | Deferiprone Capsules 250 mg | | |
| 155. | 168 | Deferiprone Capsules 500 mg | | |
| 156. | 169 | Desferrioxamine Injection IP 500 mg / Vial (For I.M. Inj and I.V., S.C. Infusion) | | |
| 157. | 171 | Dried Human Anti haemophlic Fraction IP (Dried Factor VIII Fraction IP) 250 IU/ Vial (IV use) | | |
| 158. | 172 | Enoxaparin Sodium Injection IP 60 mg | | |
| 159. | 173 | Ethamsylate Injection 250 mg/ 2 ml (IM/ IV) | | |
| 160. | 174 | Heparin Sodium Injection IP 5000 IU/ ml (IM/ IV use) | | |
| 161. | 175 | Human Albumin Solution IP 20% | | |
| 162. | 176 | Rh-Erythropoetin Injection 10000 IU | | |
| 163. | 177 | rh-Erythropoetin Injection 2000IU | | |

| | | | | |
|------|-----|--|--|--|
| 164. | 179 | Rh-Erythropoetin Injection 4000 IU | | |
| 165. | 180 | Vitamin K Injection Each ml Contains Menadione Sodium Bisulphite 10mg Equivalent to 5.2 mg of Menadione. (Aqueous Solution) | | |
| 166. | 181 | Amiodarone Tablets IP 100 mg | | |
| 167. | 182 | Amiodarone Tablets IP 200 mg | | |
| 168. | 183 | Amiodarone Hydrochloride Injection 50 mg/ ml | | |
| 169. | 184 | Amlodipine Tablets IP 2.5 mg | | |
| 170. | 185 | Amlodipine Tablets IP 5 mg | | |
| 171. | 186 | Atenolol Tablets IP 50 mg | | |
| 172. | 187 | Atorvastatin Tablets IP 10mg | | |
| 173. | 188 | Clopidogrel Tablets IP 75 mg | | |
| 174. | 189 | Digoxin Injection IP 0.25 mg/ml | | |
| 175. | 190 | Digoxin Tablets IP 0.25 mg. | | |
| 176. | 191 | Diltiazem Tabs IP 30 mg Film Coated | | |
| 177. | 192 | Dobutamine Injection 50 mg/ml | | |
| 178. | 193 | Dopamine Hydrochloride Injection 40 mg/ml | | |
| 179. | 194 | Enalapril Maleate Tablets IP 5mg | | |
| 180. | 195 | Enalapril Maleate Tablets IP 2.5 mg | | |
| 181. | 196 | Glyceryl Trinitrate Tablets IP 2.6 mg | | |
| 182. | 197 | Isosorbide dinitrate Tablets IP 5 mg | | |
| 183. | 198 | Isosorbide mononitrate Tabs IP 20 mg | | |
| 184. | 199 | Lisinopril Tablets IP 5 mg | | |
| 185. | 200 | Losartan Tablets IP 50 mg | | |
| 186. | 201 | Magnesium Sulphate Injection 50 mg/ml (50% w/v) | | |
| 187. | 202 | Methyldopa Tablets IP 250mg Film Coated | | |
| 188. | 203 | Nifedipine capsules IP 5mg | | |
| 189. | 204 | Nifedipine Tablets IP 10 mg. (Sustained Release) | | |
| 190. | 205 | Nitroglycerin Injection 5 mg/ ml | | |
| 191. | 207 | Propranolol Tablets IP 40 mg | | |
| 192. | 209 | Streptokinase Injection IP 15 lac units | | |
| 193. | 211 | Verapamil Tablets IP 40 mg Film Coated | | |
| 194. | 212 | Verapamil Injection IP 2.5 mg/ ml | | |
| 195. | 213 | Acyclovir Cream BP 5% | | |
| 196. | 217 | Glycerin IP | | |
| 197. | 218 | Liquid Paraffin IP | | |
| 198. | 219 | Ointment containing: Lidocaine IP 3%, Zinc oxide IP 5%, Hydrocortisone IP 0.25%, Allantoin IP 0.5% | | |
| 199. | 220 | Miconazole Nitrate Cream IP 2% | | |

| | | | | |
|------|-----|--|--|--|
| 200. | 221 | Povidone Iodine Ointment 5% | | |
| 201. | 222 | Povidone Iodine solution IP 5% | | |
| 202. | 223 | Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5mg, Bacitracin 250 units, Sulphacetamide 60 mg) | | |
| 203. | 224 | Silver Sulphadiazine cream 1% | | |
| 204. | 225 | Anti A Blood Grouping Serum (Anti A Monoclonal Serum) | | |
| 205. | 226 | Anti B Blood Grouping Serum (Anti B Monoclonal Serum) | | |
| 206. | 227 | Anti DRH Blood Grouping Serum | | |
| 207. | 229 | Barium sulphate suspension IP 100% | | |
| 208. | 232 | Diatrizoate Meglumine and Diatrizoate Sodium Inj USP 60% (iodine conc = 292 mg/ml) | | |
| 209. | 233 | Diatrizoate Meglumine and Diatrizoate Sodium Inj USP 76%w/v (iodine conc = 370 mg/ml) | | |
| 210. | 234 | Fluorescein Eye Drops IP 1% | | |
| 211. | 235 | Gadodiamide Inj. 0.5 mmol/ml Vial | | |
| 212. | 236 | Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 300 mg Iodine/ml. | | |
| 213. | 238 | Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 240 mg Iodine/ml | | |
| 214. | 239 | Mantoux Fluid (Tuberculin PPD IP) | | |
| 215. | 240 | Subgroup for Serum A (Anti-A1 Lectin) | | |
| 216. | 241 | Tropicamide Eye Drops IP 1% | | |
| 217. | 242 | VDRL Antigen (with +ve and- ve control)/ RPR Slide Kit | | |
| 218. | 243 | Cetrimide Tincture 0.5% w/v (Cetrimide 0.5 w/v, Average Absolute Alcohol content 65.5% v/v) | | |
| 219. | 244 | Compound Benzoin Tincture IP | | |
| 220. | 245 | Formaldehyde Solution IP | | |
| 221. | 246 | Gentian Violet Topical Solution USP 1% | | |
| 222. | 247 | Gluteraldehyde solution IP 2 % | | |
| 223. | 248 | Hydrogen Peroxide Solution IP 6% (20 ml) | | |
| 224. | 249 | Lysol (Cresol with Soap Solution) IP Cresol 50% + Soap 50% | | |
| 225. | 250 | Povidone Iodine Scrub Solution / cleansing solution 7.5% w/v Povidone Iodine (suitable for hand wash) | | |
| 226. | 252 | Surgical Spirit BP | | |
| 227. | 253 | Acetazolamide Tablets IP 250mg | | |

| | | | | |
|------|-----|---|--|--|
| 228. | 254 | Frusemide Tablets IP 40 mg | | |
| 229. | 255 | Furosemide Injection IP 10mg/ml (IM & IV use) | | |
| 230. | 256 | Hydrochlorthiazide Tablets IP 12.5 mg | | |
| 231. | 258 | Spirolactone Tablets IP 25 mg | | |
| 232. | 259 | Torsemide Tablets 10 mg | | |
| 233. | 262 | Bisacodyl Tablets IP 5 mg | | |
| 234. | 263 | Dicyclomine Tablets IP 10 mg | | |
| 235. | 264 | Dicyclomine Injection IP 10 mg /ml | | |
| 236. | 265 | Dicyclomine Hydrochloride Oral Solution IP 10mg /5ml | | |
| 237. | 266 | Domperidone Suspension 5 mg/5ml | | |
| 238. | 267 | Domperidone Tablets IP 10 mg | | |
| 239. | 268 | Hyoscine Butylbromide Injection IP 20 mg/ml | | |
| 240. | 269 | Loperamide Tablets IP 2 mg | | |
| 241. | 270 | Metoclopramide Injection IP 10mg/2ml | | |
| 242. | 271 | Metoclopramide Tablets IP 10 mg | | |
| 243. | 272 | Omeprazole Capsules IP 20 mg | | |
| 244. | 273 | Ondansetron Injection IP 2mg/ml | | |
| 245. | 274 | ORS Powder IP | | |
| 246. | 275 | Pentoprazole Injection 40 mg | | |
| 247. | 276 | Ranitidine HCL Injection IP 50mg/2ml | | |
| 248. | 277 | Ranitidine Tablets IP 150mg Film coated | | |
| 249. | 278 | Sodium Phosphates Enema BP Each 100ml contains Sodium Dihydrogen phosphate Dihydrate 10%, Disodium Hydrogen Phosphate Dodecahydrate 8% | | |
| 250. | 279 | Biphasic Isophane Insulin Injection IP (30% Soluble Insulin & 70% Isophane Insulin) Inj 40 IU/ml (r-DNA origin) | | |
| 251. | 280 | Carbimazole Tabs IP 5 mg (film Coated) | | |
| 252. | 281 | Carboprost Tromethamine Injection Each ml contains Carboprost 0.25mg/ml | | |
| 253. | 282 | Clomifene Tablets IP 25 mg | | |
| 254. | 283 | Clomiphene Tablets IP 50 mg | | |
| 255. | 284 | Conjugated Estrogen Tabs USP 0.625 mg. | | |
| 256. | 285 | Dinoprostone Cream/Gel 0.5 mg Dinoprostone in syringe | | |
| 257. | 286 | Ethinylloestradiol Tabs IP 50 mcg | | |
| 258. | 287 | Glibenclamide Tablets IP 5 mg | | |
| 259. | 288 | Gliclazide Tablets IP 40 mg | | |
| 260. | 289 | Glimepiride Tablets IP 2 mg | | |
| 261. | 290 | Glimepiride Tablets IP 1 mg | | |

| | | | | |
|------|-----|--|--|--|
| 262. | 291 | Glipizide Tablets IP 5mg | | |
| 263. | 293 | Hydroxyprogesterone Injection IP 250mg/ ml | | |
| 264. | 294 | Isophane Insulin Injection IP 40 IU/ml | | |
| 265. | 295 | Metformin Tablets IP 500 mg. (Film Coated- Scored) | | |
| 266. | 296 | Norethisterone Tablets IP 5 mg | | |
| 267. | 297 | Pioglitazone Tablets IP 15 mg | | |
| 268. | 298 | Progesterone Injection 200 mg/ 2ml | | |
| 269. | 299 | Propylthiouracil Tablets IP 50 mg | | |
| 270. | 300 | Soluble Insulin Injection IP 40 IU/ ml. (r-DNA origin) | | |
| 271. | 301 | Thyroxine Sodium Tablets IP 0.1 mg of Thyroxine Sodium equivalent to 0.091 mg of anhydrous Thyroxine Sodium | | |
| 272. | 302 | Human Anti D Immunoglobulin IP Inj. 50mcg | | |
| 273. | 303 | Human Anti D Immunoglobulin Injection 300mcg (I.M.use) | | |
| 274. | 304 | Human Anti D Immunoglobulin IP 150 mcg | | |
| 275. | 305 | Human Anti Rabies Immunoglobulin Injection 150 IU/ ml | | |
| 276. | 306 | Rabies Vaccine Human (Cell Culture) IP (Intradermal) 2.5 IU | | |
| 277. | 307 | Rabies Vaccine Human (Cell Culture) IP (Intramuscular) 2.5 IU/ dose | | |
| 278. | 308 | Snake Venum Anti Serum IP (Lyophilized) Polyvalent Anti Snake Venum, Serum Enzyme Refined. Contain purified equine globulins. 1 ml of serum neutralizes 0.6 mg of cobra venom, 0.45 mg of common krait (Bungarus) venom. | | |
| 279. | 309 | Tetanus Immunoglobulin 250 IU/ Vial | | |
| 280. | 310 | Tetanus Vaccine (adsorbed) IP | | |
| 281. | 311 | Atracurium Injection USP 10 mg/ ml | | |
| 282. | 312 | Glycopyrrolate Injection USP 0.2 mg/ml | | |
| 283. | 313 | Midazolam Injection BP 1 mg/ ml | | |
| 284. | 314 | Neostigmine Injection IP 0.5 mg/ml | | |
| 285. | 316 | Neostigmine Tablets IP 15 mg | | |
| 286. | 317 | Succinylcholine Injection IP 50 mg/ml (IV use) | | |
| 287. | 318 | Valethamate Bromide Injection 8mg / ml | | |
| 288. | 319 | Atropine Eye Ointment IP 1% | | |
| 289. | 320 | Atropine Sulphate Ophthalmic Solution USP 1% | | |
| 290. | 321 | Chloramphenicol Eye Drops 0.5% | | |
| 291. | 322 | Ciprofloxacin Eye Drops 0.3 % w/v | | |

| | | | | |
|------|-----|--|--|--|
| 292. | 323 | Ciprofloxacin Ophthalmic Ointment USP 0.3% | | |
| 293. | 324 | Hydroxypropylmethyl cellulose Solution 20 mg/ml | | |
| 294. | 326 | Pilocarpine Eye Drops IP 2% | | |
| 295. | 328 | Sulfacetamide Eye drops 20% | | |
| 296. | 329 | Timolol Eye Drops IP 0.25% w/v | | |
| 297. | 330 | Tobramycin and Dexamethasone Ophthalmic Suspension USP 0.3%+0.1% | | |
| 298. | 331 | Tobramycin Eye Drops 0.3% | | |
| 299. | 332 | Tobramycin Ophthalmic Ointment USP 0.3% | | |
| 300. | 333 | Isoxsuprine Injection IP 5 mg/ml | | |
| 301. | 334 | Isoxsuprine Tablets IP 20 mg | | |
| 302. | 335 | Methylergometrine Injection IP 0.2 mg/ml | | |
| 303. | 336 | Methylergometrine Tablet IP 0.125 mg | | |
| 304. | 337 | Misoprostol Tablets 200 mcg | | |
| 305. | 338 | Oxytocin Injection IP 5 IU/ml | | |
| 306. | 339 | Alprazolam Tablets IP 0.25 mg | | |
| 307. | 340 | Alprazolam Tablets IP 0.5 mg | | |
| 308. | 341 | Amitriptyline Tablets IP 25 mg Film Coated | | |
| 309. | 342 | Chlordiazepoxide Tablets IP 10mg | | |
| 310. | 343 | Chlorpromazine Tablets 100 mg (Coated Tablet) | | |
| 311. | 344 | Chlorpromazine Tablets IP 25 mg (Coated Tablet) | | |
| 312. | 345 | Chlorpromazine Tablets IP 50 mg (Coated Tablets) | | |
| 313. | 346 | Chlorpromazine Inj. IP 25mg/ml | | |
| 314. | 347 | Clomipramine Capsules IP 25 mg | | |
| 315. | 348 | Clonazepam Tablets IP 1 mg | | |
| 316. | 349 | Diazepam Injection IP 10mg/2ml (1M/IV use) | | |
| 317. | 350 | Diazepam Tablets IP 5 mg | | |
| 318. | 351 | Escitalopram Tablets 10 mg | | |
| 319. | 352 | Fluoxetine Capsules IP 20 mg | | |
| 320. | 353 | Haloperidol Injection IP 5 mg/ml | | |
| 321. | 354 | Haloperidol Tablets IP 1.5 mg | | |
| 322. | 355 | Haloperidol Tablets IP 5 mg | | |
| 323. | 356 | Imipramine Tablets IP 25 mg (Coated Tablets) | | |
| 324. | 357 | Imipramine Tablets IP 75 mg (Coated) | | |
| 325. | 358 | Lithium Carbonate Tablets IP 300 mg | | |
| 326. | 359 | Lorazepam Injection 2 mg/ ml | | |
| 327. | 360 | Olanzapine Tablets IP 5 mg | | |
| 328. | 361 | Risperidone Tablets 2 mg | | |
| 329. | 362 | Risperidone Tablets 1 mg | | |

| | | | | |
|------|-----|---|--|--|
| 330. | 363 | Sertraline Tablets 50 mg | | |
| 331. | 364 | Trifluoperazine Tablets IP 5 mg Coated | | |
| 332. | 365 | Aminophylline Injection IP 25 mg/ml | | |
| 333. | 366 | Beclomethasone Inhalation IP 200 mcg/ dose | | |
| 334. | 367 | Budesonide Nebulizer Suspension 0.25mg/ ml | | |
| 335. | 368 | Cough Syrup Each 5ml contains Chloropheniramine Maleate IP 3mg Ammonium Chloride 130mg, Sodium Citrate 65 mg, Menthol 0.5 mg, Syrup Q.S. | | |
| 336. | 369 | Ipratropium Bromide Nebulizer Solution 250 mcg/ ml | | |
| 337. | 370 | Salbutamol Tablets IP 4 mg | | |
| 338. | 371 | Salbutamol Inhalation 100 mcg /dose | | |
| 339. | 372 | Salbutamol Nebuliser Solution BP 5 mg/ ml | | |
| 340. | 373 | Salbutamol Tablets IP 2 mg | | |
| 341. | 374 | Theophylline and Etofylline Injection (Anhydrous Theophylline 50.6mg + Etofylline 169.4 mg) | | |
| 342. | 375 | Theophylline and Etofylline Tablets (Theophylline IP 23mg + Etofylline IP 77 mg) | | |
| 343. | 376 | Theophylline Tablets 400 mg (Sustained Release/ Controlled Release) | | |
| 344. | 377 | Compound Sodium Lactate inj. IP | | |
| 345. | 378 | Dextrose Injection IP 25 % w/v | | |
| 346. | 379 | Dextrose injection 10% | | |
| 347. | 380 | Dextrose injection 5% isotonic | | |
| 348. | 381 | Multiple Electrolytes & Dextrose Injection Type I IP (Electrolyte 'P' Injection) | | |
| 349. | 382 | Multiple Electrolytes & Dextrose Injection Type III IP Electrolyte "M" Injection (I.V.) | | |
| 350. | 383 | Potassium Chloride Injection 0.15 gm/ml | | |
| 351. | 384 | Potassium chloride Oral Solution U.S.P 500mg/ 5ml | | |
| 352. | 385 | Sodium Chloride and Dextrose Inj. I.P (0.9%+5%) | | |
| 353. | 386 | Sodium Chloride Injection IP | | |
| 354. | 387 | Ascorbic Acid Tablets IP 500 mg | | |
| 355. | 388 | Calcium Gluconate Injection IP 10% (IV use) | | |
| 356. | 390 | Ferrous Sulphate with Folic Acid Tab. Each film coated Tab. Containing Dried Ferrous Sulphate IP- equivalent to 100 mg Elemental Iron and Folic Acid IP 0.5 mg | | |
| 357. | 391 | Ferrous Sulphate with Folic Acid Tab. (Paediatric) Each film coated Tab. Containing | | |

| | | | | |
|------|-----|--|--|--|
| | | dried Ferrous Sulphate IP-equivalent to 20 mg Elemental Iron and Folic Acid IP-100 | | |
| 358. | 392 | Folic Acid Tablets IP 5 mg | | |
| 359. | 393 | Multivitamin Drops Each ml contains Vit-A -3000 IU, Vit-D3-300 IU, Vit-B1 -1mg, Riboflavine Phosphate Sodium -2mg, D-Panthenol -2.5mg, Niacinamide -10mg, Pyridoxine HCL-1mg, Cyanocobalamin 1mcg, Lysine HCL 10mg | | |
| 360. | 394 | Multivitamin Tablets NFI Formula Sugar coated. Vit A 2500 IU, Vit B1-2mg, Vit- B6-0.5mg, Vit-C-50mg, Calcium Pantothenate-1mg, Vit-D3-200IU, Vit-B2 2 mg, Niacinamide-25mg, Folic Acid-0.2 mg | | |
| 361. | 395 | Vitamin B Complex Injection NFI | | |
| 362. | 397 | Vitamin – B complex tablet NFI(prophylactic) B1- 2mg, B2- 2mg, B6-0.5mg, Niacinamide 25mg, Calcium pantothenate 1mg (With appropriate overages) | | |
| 363. | 398 | Black Disinfectant Fluid (Phenyl) (As per Schedule "O" Grade – III | | |
| 364. | 399 | Concentrated Haemodialysis Fluid B.P Acetate concentrate in 10 Litre Cans. Each 1000ml After 1:34 dilutions should provide Sodium Chloride 135 to 140 meq/Litre sodium Acetate 35-38 meq/Litre Potassium Chloride 1.5-2 meq/Litre Magnesium chloride 1-1.5 meq/Litre calcium chloride 0-3 meq/Litre (depending on local condition) water purified to 1000 ml | | |
| 365. | 401 | Peritoneal Dialysis Solution IP | | |
| 366. | 402 | Sodium Bicarbonate Injection IP 7.5% w/v | | |
| 367. | 404 | Water for Injection IP | | |
| 368. | 405 | Polygeline 3.5% Solution with electrolytes for IV Infusion | | |
| 369. | 406 | Factor- IX Concentrate (Purified) 600 IU (Human Coagulation Factor IX) | | |
| 370. | 407 | Anti-Inhibitor coagulation Complex (Human Plasma Protein with a Factor VIII Inhibitor Bypassing Activity of 500 IU per Vial) | | |
| 371. | 408 | Rabies Antiserum IP (Equine) 300 units per ml [contains equine anti-rabies immunoglobulin fragments](I.M./SC use) | | |
| 372. | 409 | Vitamin A Paediatric oral solution IP Vitamin A Concentrate Oil IP Each ml | | |

| | | | | |
|------|-----|--|--|--|
| | | contains vitamin A 100000 IU | | |
| 373. | 410 | Labetalol Tablets IP 100mg | | |
| 374. | 411 | Labetalol Hydrochloride Injection BP/USP 20mg/4ml | | |
| 375. | 412 | Ampicillin Capsules IP 500 mg | | |
| 376. | 413 | Nitrofurantoin Tablets IP 100mg | | |
| 377. | 414 | Hyoscine Butyl Bromide Tablets IP 10mg (Coated Tablets) | | |
| 378. | 415 | Drotaverine Tablets 40 mg | | |
| 379. | 416 | Hydroxyethyl Starch (130/0.4) 6% w/v with Sodium Chloride 0.9% w/v Intravenous Infusion | | |
| 380. | 417 | Cloxacillin sodium Injection IP 500 mg | | |
| 381. | 418 | Betamethasone Sodium Phosphate Injection IP 4 mg/ml | | |
| 382. | 419 | Vecuronium Bromide for Injection 4 mg (Freeze Dried) | | |
| 383. | 420 | Phenobarbitone Injection IP 200mg/ml | | |
| 384. | 421 | Flurbiprofen Sodium Ophthalmic Solution USP 0.03% w/v | | |
| 385. | 423 | Hyaluronidase Injection IP Each vial contains Hyaluronidase IP 1500 IU | | |
| 386. | 424 | Lidocaine Hydrochloride Topical Solution USP 4% | | |
| 387. | 425 | Fluconazole Eye Drops 0.3% | | |
| 388. | 426 | Co-trimoxazole Tablets P (Trimethoprin 20 mg and Sulphamethoxazole 100mg | | |
| 389. | 427 | Cephalexin Oral Suspension IP (Cephalexin Dry Syrup IP) 125 mg/ 5 ml | | |
| 390. | 428 | Ofloxacin Suspension 50mg/ 5ml | | |
| 391. | 429 | Furazolidone Tablets IP 100 mg | | |
| 392. | 430 | Tinidazole Tablets IP 300 mg (Film Coated) | | |
| 393. | 431 | Tinidazole Tablets IP 500 mg (Film Coated) | | |
| 394. | 432 | Salbutamol Syrup IP 2mg/ 5ml | | |
| 395. | 433 | Ranitidine Tablets IP 300 mg Film coated | | |
| 396. | 434 | Famotidine Tablets IP 20 mg | | |
| 397. | 435 | Famotidine Tablets IP 40 mg | | |
| 398. | 436 | Indomethacin Capsules IP 25 mg | | |
| 399. | 437 | Slow Diclofenac Tablete BP / Diclofenac sodium extended release Tablet USP 100 mg (sustained release) | | |
| 400. | 438 | Dicyclomine Hydrochloride and Activated dimethicone suspension. Each ml contains: Dicyclomine Hydrochloride 10 mg, Activated | | |

| | | | | |
|------|-----|---|--|--|
| | | dimethicone 40 mg | | |
| 401. | 440 | Dextromethorphan Hydrobromide Syrup IP 13.5mg / 5ml | | |
| 402. | 441 | Calcium & Vitamin D3 Suspension (Each 5 ml contains Calcium Carbonate equivalent to elemental Calcium 250 mg, Vitamin D3 - 125 IU) | | |
| 403. | 442 | Saline Nasal Solution (Drops) (Sodium chloride 0.65%) | | |
| 404. | 443 | Clotrimazole mouth paint (Clotrimazole 1% w/v) | | |
| 405. | 444 | Aspirin Delayed Release Tablets USP. Each enteric coated tablet contains Acetyl Salicylic Acid 75 mg | | |
| 406. | 445 | Beclomethasone, Neomycin and Clotrimazole Cream (Beclomethasone dipropionate 0.025%, Neomycin sulphate 0.5% Clotrimazole 1%) | | |
| 407. | 446 | Gamma Benzene Hexachloride Lotion 1% (Lindane lotion USP) | | |
| 408. | 447 | Chlorhexidine Gluconate Solution IP 5% | | |
| 409. | 448 | Iron and Folic Acid Syrup. Each 5ml contains Ferrous Fumerate 100mg, Folic Acid 500 mcg | | |
| 410. | 449 | Surgical Spirit BP | | |
| 411. | 450 | Povidone Iodine Solution IP 5% | | |
| 412. | 451 | Metformin Hydrochloride Sustained Release Tablets IP 1000 mg | | |
| 413. | 452 | Glipizide and Metformin Hydrochloride tablets USP (Glipizide 5mg, Metformin Hydrochloride 500 mg) | | |
| 414. | 453 | Glibenclamide and Metformin Hydrochloride (SR) Tablets [Glibenclamide 5mg, Metformin Hydrochloride 500 mg (Sustained Release)] | | |
| 415. | 454 | Metformin Hydrochloride (Sustained Release) and Glimperiride Tablets {Metformin Hydrochloride (Sustained Release) 500 mg, Glimipiride 1 mg} | | |
| 416. | 455 | Metformine Hydrochloride (Sustained Release) and Glimperiride Tablets {Metformine Hydrochloride (Sustained Release) 500 m, Glimipiride 2 mg} | | |
| 417. | 456 | Glimperiride, Pioglitazone and Metformin Hydrochloride (Sustained Release) Tablets Each Tablet contains Glimepiride 2mg, Pioglitazone 15mg, Metformin Hydrochloride(Sustained release) 500 mg | | |
| 418. | 457 | Amlodipine and Enalapril Maleate Tablet (Amlodipine Besilate equivalent to Amlodipine | | |

| | | | | |
|------|-----|---|--|--|
| | | 5mg, Enalapril maleate 5mg) | | |
| 419. | 458 | Losarton Potassium & Amlodipine tablets IP (Losarton Potassium 50 mg, Amlodipine Besilate eq. to Amlodipine 5mg) | | |
| 420. | 459 | Losarton Potassium & Hydrochlorothiazide Tablets IP (Losarton Potassium 50 mg, Hydrochlorothiazide 12.5 mg) | | |
| 421. | 460 | Amlodipine and Lisinopril Tablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Lisinopril eq. to lisinopril (anhydrous) 5mg] | | |
| 422. | 461 | Amlodipine and Atenolol Tablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Atenolol 50mg] | | |
| 423. | 462 | Atenolol Tablets IP 25 mg | | |
| 424. | 463 | Enalapril Maleate Tablets IP 10 mg | | |
| 425. | 464 | Hydrochlorothiazide Tablets IP 25 mg | | |
| 426. | 465 | Lisinopril Tablets IP 10 mg | | |
| 427. | 466 | Lisinopril Tablets IP 2.5 mg | | |
| 428. | 467 | Losartan Tablets IP 25 mg | | |
| 429. | 468 | Piperacillin and Tazobactam for Injection USP 4 gm + 500 mg | | |
| 430. | 469 | Prednisolone Tablets IP 10 mg | | |
| 431. | 470 | Prednisolone Tablets IP 20 mg | | |
| 432. | 471 | Torsemide Injection 10 mg/ml | | |
| 433. | 472 | Zinc Sulphate Dispersible Tablets IP Elemental Zinc 10 mg | | |
| 434. | 473 | Amoxycillin Oral Suspension IP (Dry Syrup) 125 mg/ 5 ml | | |
| 435. | 474 | Carbamazepine Oral Suspension 100 mg/ 5ml | | |
| 436. | 475 | Cefpodoxime Dispersible Tablets 50 mg | | |
| 437. | 476 | Cephalexin Tablets 125 mg (Dispersible Tablets) | | |
| 438. | 477 | Ibuprofen Oral Suspension BP/USP 100 mg/ 5 ml | | |
| 439. | 478 | Metoclopramide Hydrochloride Syrup IP 5 mg/5ml | | |
| 440. | 479 | Sodium Valproate Oral Solution IP 200 mg / 5 ml | | |
| 441. | 480 | Diphtheria Antitoxin 10000 IU | | |
| 442. | 481 | Meropenem Injection IP 1 g | | |
| 443. | 482 | Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 300 mg Iodine/ml. | | |
| 444. | 483 | Diclofenac Sodium and Paracetamol Tablets Diclofenac Sodium 50 mg + Paracetamol 325 mg | | |

| | | | | |
|------|-----|--|--|--|
| 445. | 484 | Timolol Eye Drops IP 0.5 % w/v | | |
| 446. | 485 | Homatropine Eye Drops IP 2 % | | |
| 447. | 486 | Travoprost Ophthalmic Solution 0.004% | | |
| 448. | 487 | Brimonidine Tartrate and Timolol Maleate Eye Drops 0.15% + 0.5% | | |
| 449. | 488 | Iron Sucrose Injection USP (For IV Use) Each ml contain: Ferric hydroxide in complex with Sucrose equivalent to elemental Iron 20 mg | | |
| 450. | 491 | Sevoflurane | | |
| 451. | 492 | Aceclofenac and Paracetamol Tablets Aceclofenac 100 mg and Paracetamol 325 mg | | |
| 452. | 493 | Diclofenac Gel: Diclofenac Diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3% and Menthol 5% | | |
| 453. | 494 | Etoricoxib Tablets 60 mg | | |
| 454. | 495 | Etoricoxib Tablets 120 mg | | |
| 455. | 496 | Mefenamic Acid Tablets BP 500 mg | | |
| 456. | 497 | Anticold syrup: Each 5 ml contains Phenylephrine Hydrochloride 2.5 mg, Chlorpheniramine maleate 1 mg, and Paracetamol 125 mg | | |
| 457. | 498 | Cetirizine, Phenylephrine & Paracetamol Tablets Cetirizine 5 mg, Phenylephrine 10 mg & Paracetamol 325 mg | | |
| 458. | 499 | Cetirizine syrup IP 5 mg/ 5ml | | |
| 459. | 500 | Acetylcystine Solution USP (Injection) 200 mg/ ml | | |
| 460. | 501 | Activated Charcoal Tablet 250 mg | | |
| 461. | 502 | Acyclovir Intravenous Infusion IP 250 mg | | |
| 462. | 503 | Acyclovir Intravenous Infusion IP 500 mg | | |
| 463. | 504 | Amikacin Injection IP 250 mg | | |
| 464. | 505 | Amoxicillin and Potassium Clavulante Injection IP 600 mg | | |
| 465. | 506 | Amoxicillin and Potassium Clavulante Injection IP 1.2 g | | |
| 466. | 507 | Amoxicillin and Potassium Clavulante Oral Suspension IP 200 mg + 28.5 mg per 5 ml | | |
| 467. | 508 | Artesunate Injection 60 mg | | |
| 468. | 509 | Aztreonam Injection USP 500 mg | | |
| 469. | 510 | Cefepime Injection IP 500 mg | | |
| 470. | 511 | Cefixime Oral Suspension IP 25 mg/ ml (Paediatric Drops) | | |
| 471. | 512 | Cefuroxime Axetil Tablets IP 250 mg | | |
| 472. | 513 | Clindamycin Capsules IP 150 mg | | |

| | | | | |
|------|-----|---|--|--|
| 473. | 514 | Clindamycin Capsules IP 300 mg | | |
| 474. | 515 | Levofloxacin Tablets IP 250 mg | | |
| 475. | 516 | Linezolid Tablets IP 600 mg | | |
| 476. | 517 | Linezolid Injection 200 mg/ 100 ml | | |
| 477. | 518 | Mefloquine Tablets IP 250 mg | | |
| 478. | 519 | Metronidazole & Norfloxacin suspension 100 + 100 mg per 5 ml | | |
| 479. | 520 | Ofloxacin and Ornidazole Tablets (Ofloxacin 200 mg and Ornidazole 500 mg) | | |
| 480. | 521 | Ofloxacin Infusion IP 200mg/ 100 ml (in NaCl Inj) | | |
| 481. | 522 | Pyrimethamine and Sulphadoxine Tablets IP (Pyrimethamine 37.5 mg and Sulphadoxine 750 mg) | | |
| 482. | 523 | Vancomycin for Intravenous Infusion IP 500 mg | | |
| 483. | 524 | Vancomycin for Intravenous Infusion IP 1 g | | |
| 484. | 525 | Alpha Interferon Injection (Interferon Alpha-2 concentrated Solution IP) 3 million unit | | |
| 485. | 526 | Carboplatin Injection 150 mg USP/ BP | | |
| 486. | 527 | Carboplatin Injection 450 mg USP/ BP | | |
| 487. | 528 | Cisplatin Injection IP 10 mg/ 10 ml | | |
| 488. | 529 | Dacarbazine Injection 500 mg USP/ BP | | |
| 489. | 530 | Filgrastim Injection (Granulocyte Colony Stimulation Factor) 300 mcg | | |
| 490. | 531 | Gemcitabine for Injection USP 200 mg | | |
| 491. | 532 | Gemcitabine for Injection USP 1 gm | | |
| 492. | 533 | Ifosfamide Injection USP/ BP 1 gm | | |
| 493. | 534 | Imatinib Tablets 400 mg | | |
| 494. | 535 | Mesna Injection 200 mg | | |
| 495. | 536 | Methotrexate Tablets IP 10 mg | | |
| 496. | 537 | Mitomycine for Injection USP 10 mg | | |
| 497. | 538 | Oxaliplatin Injection USP 50 mg | | |
| 498. | 539 | Bromocriptine Tablets IP 1.25 mg | | |
| 499. | 540 | Bromocriptine Tablets IP 2.5 mg | | |
| 500. | 541 | Betahistine Tablets IP 8 mg | | |
| 501. | 542 | Betahistine Tablets IP 16 mg | | |
| 502. | 543 | Cinnarizine Tablets IP 25 mg | | |
| 503. | 544 | Cinnarizine Tablets IP 75 mg | | |
| 504. | 545 | Tranexamic Acid Tablets BP 500 mg | | |
| 505. | 546 | Warfarin Sodium Tablets IP 5 mg | | |
| 506. | 547 | Adenosine Injection USP 6 mg/ 2 ml | | |
| 507. | 548 | Atorvastatin Tablets IP 40 mg | | |

| | | | | |
|------|-----|--|--|--|
| 508. | 549 | Clopidogrel and Aspirin Tablets Clopidogrel 75 mg and Aspirin 75 mg | | |
| 509. | 550 | Fenofibrate Capsules IP 200 mg | | |
| 510. | 551 | Isoprenaline Injection IP 2 mg/ml | | |
| 511. | 552 | Metoprolol Tablets IP 25 mg | | |
| 512. | 553 | Metoprolol Succinate Extended Release Tablets USP 50 mg | | |
| 513. | 554 | Noradrenaline Injection IP 2 mg/ ml | | |
| 514. | 555 | Prazosin Tablets (Extended Release) 2.5 mg | | |
| 515. | 556 | Telmisartan Tablets IP 40 mg | | |
| 516. | 557 | Urokinase Injection 5 Lac Unit (Lyophilized) | | |
| 517. | 558 | Betamethasone Dipropionate Cream IP 0.05% | | |
| 518. | 559 | Betamethasone Lotion IP 0.05% | | |
| 519. | 560 | Clindamycin Phosphate Gel USP 1% | | |
| 520. | 561 | Clobetasol Propionate Cream USP/ BP 0.05% | | |
| 521. | 562 | Coal tar 4.25% and Salicylic Acid 2% Solution | | |
| 522. | 563 | Dithranol Ointment IP 0.5% | | |
| 523. | 564 | Glycerin IP | | |
| 524. | 565 | Ketoconazole Cream 2% | | |
| 525. | 566 | Neomycin sulphate and Bacitracin ointment USP 5 mg + 500 IU/ gm | | |
| 526. | 567 | Permethrin Lotion 1% | | |
| 527. | 568 | Permethrin Lotion 5% | | |
| 528. | 569 | Permethrin Cream 5% | | |
| 529. | 570 | Tretinoin Cream USP 0.025% | | |
| 530. | 571 | Povidone Iodine Ointment USP 5% | | |
| 531. | 572 | Povidone Iodine Solution IP 10% | | |
| 532. | 573 | Silver Sulphadiazine Cream USP 1% | | |
| 533. | 574 | Spironolactone Tablets IP 50 mg | | |
| 534. | 575 | Finasteride Tablets IP 5 mg | | |
| 535. | 576 | Tamsulosin HCl Tablets 0.4 mg | | |
| 536. | 577 | Terazosin Tablets USP 1 mg | | |
| 537. | 578 | Terazosin Tablets USP 2 mg | | |
| 538. | 579 | Flavoxate Tablets USP/ BP 200 mg | | |
| 539. | 580 | Chlorhexidine Mouthwash BP 0.2% / Chlorhexidine Oral rinse USP 0.2% | | |
| 540. | 581 | Dental Gel: Choline salicylate 8.7%, Benzalkonium Chloride 0.01%, Lignocaine HCl 2% (flavoured gel base) | | |
| 541. | 582 | Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base) | | |
| 542. | 583 | Gum Paint containing Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1% | | |

| | | | | |
|------|-----|--|--|--|
| 543. | 584 | Metronidazole 1% and Chlorhexidine gluconate 0.25% Gel | | |
| 544. | 585 | Ciprofloxacin 0.3% and Dexamethasone 0.1% Ear Drops Ciprofloxacin and Dexamethasone Otic Suspension USP | | |
| 545. | 586 | Clotrimazole 1% with Beclomethasone Dipropionate 0.025% Ear Drops | | |
| 546. | 587 | Clotrimazole 1% with lignocaine 1% Ear Drops | | |
| 547. | 588 | Neomycin, Polymixin B and Hydrocortisone Ear Drops (Neomycin sulphate 3400 IU, Polymixin B Sulphate 10000 IU, and Hydrocortisone 10 mg per ml) Neomycin and Polymixin B Sulfate and Hydrocortisone Otic Solution USP | | |
| 548. | 589 | Ceruminolytic Drops (Wax dissolving ear drops): Paradichlorobenzene 2%, Benzocaine 2.7%, Chlorbutol 5%, Turpentine oil 15% | | |
| 549. | 590 | Domeperidone Oral Drops 10 mg/ ml | | |
| 550. | 591 | Drotaverine & Mefenamic Acid Tablets Drotaverine 80 mg and Mefenamic Acid 250 mg | | |
| 551. | 592 | Lactic Acid Bacillus Tablets 60 million spores | | |
| 552. | 593 | Lactulose solution USP/ BP 10 gm/ 15 ml or 3.35gm/5 ml | | |
| 553. | 594 | Liquid Paraffin IP | | |
| 554. | 595 | Ondansetron Orally Disintegrating Tablets IP 4 mg | | |
| 555. | 596 | Pantoprazole 40 mg and Domperidone 30 mg SR Capsules Pantoprazole as enteric coated pellets, and Domperidone as sustained release pellets | | |
| 556. | 597 | Ursodeoxycholic Acid Tablets BP 300 mg | | |
| 557. | 598 | Allopurinol Tablets IP 100 mg | | |
| 558. | 599 | Hydroxychloroquine Sulphate Tablets USP/ BP 200 mg | | |
| 559. | 600 | Leflunomide Tablets USP 10 mg (Film coated) | | |
| 560. | 601 | Leflunomide Tablets USP 20 mg (Film coated) | | |
| 561. | 602 | Sulfasalazine Delayed Release Tablets USP/ Gastroresistant Sulfasalazine Tablets BP 500 mg | | |
| 562. | 603 | Gliclazide and Metformin Tablets Gliclazide 80 mg and Metformin Hydrochloride 500 mg | | |
| 563. | 604 | Glucagon for Injection USP 1 mg/ ml | | |
| 564. | 605 | Medroxyprogesterone acetate Tablets IP 10 mg | | |
| 565. | 606 | Testosterone Propionate Injection IP 25 mg/ 1 ml | | |
| 566. | 607 | Thyroxine Tablets IP 50 mcg | | |
| 567. | 608 | Octreotide Injection 50 mcg/ ml | | |
| 568. | 609 | Chlorzoxazone Tablets USP 250 mg | | |
| 569. | 610 | Chlorzoxazone , Diclofenac Sodium & | | |

| | | | | |
|------|------|---|--|--|
| | | Paracetamol Tablets (Chlorzoxazone 250 mg, Diclofenac Sodium 50 mg & Paracetamol 325 mg) | | |
| 570. | 611 | Betaxolol Ophthalmic Solution USP / Betaxolol Eye Drops, Solution BP 0.25% | | |
| 571. | 612 | Betaxolol Ophthalmic Solution USP/ Betaxolol eye Drops, Solution BP 0.5% | | |
| 572. | 613 | Carboxymethylcellulose Sodium Lubricant Eye Drops 0.5% | | |
| 573. | 614 | Phenylephrine Hydrochloride Ophthalmic Solution USP/ Phenylephrine Eye Drops BP 5% | | |
| 574. | 615 | Mifepristone Tablets 200 mg | | |
| 575. | 616 | Formoterol Fumerate and Budesonide Powder for Inhalation IP 6 mcg + 200 mcg | | |
| 576. | 617 | Budesonide Powder for Inhalation BP 200 mcg | | |
| 577. | 618 | Ipratropium Powder for Inhalation IP 40 mcg | | |
| 578. | 619 | Terbutaline Tablets IP 2.5 mg | | |
| 579. | 620 | Xylometazoline Nasal Drops IP 0.1 % | | |
| 580. | 621 | Sodium Chloride Injection IP | | |
| 581. | 622 | Calcium Carbonate & vitamin D3 Tablets (Elemental Calcium 500 mg, Vitamin D3- 250 IU) Calcium with Vitamin D Tablets USP/ Calcium and Colecalciferol Tablets BP | | |
| 582. | 623 | Cholecalciferol granules 60, 000 IU/ gm | | |
| 583. | 624 | Mecobalamin Injection 500 mcg/ ml | | |
| 584. | 625 | Nicotinamide Tablets IP 50 mg | | |
| 585. | 626 | Pyridoxine Tablets IP 10 mg | | |
| 586. | 627 | Pyridoxine Tablets IP 40 mg | | |
| 587. | 628 | Riboflavin Tablets IP 5 mg | | |
| 588. | 629 | Thiamine Tablets IP 100 mg | | |
| 589. | 630 | Calcitriol Capsules IP 0.25 mcg | | |
| 590. | 631 | Alendronate Sodium Tablets USP/ BP 35 mg | | |
| 591. | 632 | Mannitol with Glycerin Injection 10% +10% w/v (For Intravenous Infusion) | | |
| 592. | 633 | Normal Human Intravenous Immunoglobulin 5 g/ 100 ml | | |
| 593. | 634 | Pregabalin Capsules IP 75 mg | | |
| 594. | 635 | Surfactant for intratreacheal instillation (natural bovine lung surfactant) | | |
| 595. | 636 | Ramipril Tablet IP 2.5 mg | | |
| 596. | 637 | Vitamin –A Capsule USP, Soft Gelatin Capsule contains Vit-A 50000 units | | |
| 597. | 638 | Neostigmine Injection IP 2.5mg/5 ml | | |
| 598. | 100A | Chloroquine Suspension IP 50 mg/5ml | | |

| | | | | |
|------|------|--|--|--|
| 599. | 214A | Calamine Lotion IP | | |
| 600. | 215A | Certimide Cream IP | | |
| 601. | 216A | Fusidic Acid Cream IP 2% | | |
| 602. | 231A | Diagnostic Sticks for Urine Sugar and Albumin | | |
| 603. | 257A | Mannitol Injection IP 20% w/v | | |
| 604. | 260A | Antacid Tablets. Formula: Each chewable tablet contains Magnesium Trisilicate 250mg, Dried Aluminium Hydroxide Gel 120mg, Peppermint oil | | |
| 605. | 261A | Antacid Liquid, Each 5 ml contains Dried Aluminium Hydroxide Gel 250 mg, Magnesium Hydroxide 250 mg, Activated polydimethyl siloxane 50 mg | | |
| 606. | 439A | Dicyclomine and Paracetamol Tablets Dicyclomine Hydrochloride 20 mg + Paracetamol 325 mg Tablets | | |
| 607. | 80A | Azithromycin Tablets IP 500 mg | | |
| 608. | 489P | IRON AND FOLIC ACID TABLETS (IFA – WIFS) Each enteric coated tablet contains: Dried Ferrous Sulphate IP equivalent to Ferrous iron 100 mg Folic Acid IP 0.5 mg The tablets are Blue coloured (Indigo Carmine) | | |
| 609. | 490P | IRON AND FOLIC ACID TABLETS (IFA – Small) Each enteric coated tablet contains: Dried Ferrous Sulphate IP equivalent to Ferrous iron 30 mg Folic Acid IP 250 mcg The tablets are Blue coloured (Indigo Carmine) | | |
| 610. | 0 | Donepezil Tablets 5 mg | | |
| 611. | 0 | Baclofen Tablets 10 mg | | |
| 612. | 0 | Docetaxel Injection 20, 80, 120 mg | | |
| 613. | 0 | Insulin Glargine 100 IU/ml | | |
| 614. | 0 | Nicotine Gum Tablets 2, 4 mg | | |
| 615. | 0 | Bupropion Tablets 150 mg | | |
| 616. | 0 | Antimalarial ACT Combi pack containing Artesunate Tablets and Sulphadoxine + Pyremethamine Tablets | | |
| 617. | 0 | Artesunate Injection 60 mg in Combi pack form with Sodium Chloride Injection IP 0.9% w/v and Sodium bicarbonate Injection IP 5% w/v | | |
| 618. | 0 | Sterility Test alone of any product | | |

